← All trials
NCT04589949
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2020
- Primary completion
- Nov 1, 2022
- Completion date
- Nov 1, 2023
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 690
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamReponsible party - principal investigator
- Leiden UniversityCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- SanquinCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.